መነሻ › Multiple Sclerosis › አሪዞና
በአሪዞና ለMultiple Sclerosis የሚደረጉ ክሊኒካዊ ጥናቶች
ለMultiple Sclerosis የሚደረጉ 6 ጥናቶች በአሪዞና ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በአሪዞና ውስጥ ያሉ ከተሞች
Official study text (English)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Perseverance Research Center,LLC, Scottsdale
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06782490A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Clinical Endpoints, LLC, Scottsdale
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT07609719A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Gilbert
- TG Therapeutics Investigational Trial Site, Phoenix
- TG Therapeutics Investigational Trial Site, Scottsdale
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT06433752RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Arizona, Tucson
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Center for Neurology and Spine - Phoenix - East Bell Road- Site Number : 8400195, Phoenix
- Perseverance Research Center- Site Number : 8400138, Scottsdale
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 60 · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT07325292A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Ctr for Neurology and Spine, Phoenix
- AZ Integrated Neuro and Spine, Phoenix
- Center for Neurosciences, Tucson
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁላይ 2026 · NCT07225504ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።